TSTickerStarGet alerts

Beyond Air Reports Q2 FY2027 Revenue of $2.3 Million, Up 28% Year-Over-Year

Beyond Air reported record quarterly revenue of $2.3 million for the quarter ended September 30, 2026, representing approximately 28% year-over-year growth, driven by continued adoption of the first-generation LungFit PH system. The company reported a net loss attributable to common stockholders of $7.8 million, or a loss of $3.76 per basic and diluted share, compared with a net loss of $7.9 million, or a loss of $24.98 per basic and diluted share, for the same period last year. Beyond Air reaffirmed its revenue...

Share this story

Forward guidance

RevenueCY2026
$8 million
RevenueCY2027
$16 million - $18 million112.5% from CY2026 midpoint

Key takeaways

  • Revenue: Record quarterly revenue of $2.3 million, up 28% year-over-year and up 31% sequentially from Q1 FY2027.

  • EPS: Net loss of $3.76 per basic and diluted share, compared with a loss of $24.98 per share in the prior year period (prior period adjusted for 1-for-20 reverse stock split in July 2026).

  • Operating expenses: R&D decreased to $1.6 million from $2.5 million due to completion of second-generation LungFit PH development; SG&A decreased to $4.6 million from $4.9 million.

  • Other expense increased to $2.2 million from $0.6 million, driven by increased debt and interest expense plus a charge for scrapped materials.

  • Cash position: $18.5 million in cash, cash equivalents, restricted cash, and marketable securities as of September 30, 2026.

  • FDA status: PMA supplement for second-generation LungFit PH remains under FDA review; audit-readiness process expected to complete mid-December.

  • Strategic update: Announced definitive agreement for UNIVO Pharmaceutical Industries to acquire controlling interest in NeuroNOS Israel Ltd.

Key metrics

Total RevenueQ2 FY2027 (quarter ended September 30, 2026)
$2.3 million28% year-over-year growth
Total Revenue (Prior Year)Q2 FY2026 (quarter ended September 30, 2025)
$1.8 million
Net Loss Attributable to Beyond AirQ2 FY2027 (quarter ended September 30, 2026)
$7.8 millionImproved from $7.9 million net loss
GAAP Basic and Diluted EPSQ2 FY2027 (quarter ended September 30, 2026)
($3.76)Improved from ($24.98) per share (adjusted for 1-for-20 reverse stock split)
Operating LossQ2 FY2027 (quarter ended September 30, 2026)
$6.0 millionImproved from $7.7 million operating loss
R&D ExpensesQ2 FY2027 (quarter ended September 30, 2026)
$1.6 millionDecreased from $2.5 million
SG&A ExpensesQ2 FY2027 (quarter ended September 30, 2026)
$4.6 millionDecreased from $4.9 million
Cash and Cash EquivalentsAs of September 30, 2026
$5.4 million

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow XAIR in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert